MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
INKT — MiNK Therapeutics, Inc. Common Stock
NasdaqMiNK Therapeutics, Inc. Common Stock
$12.20
-0.24(-1.93%)
- O
- 12.51
- H
- 12.83
- L
- 12.10
- V
- 27.44K
⏱️ End-of-day dataAs of Oct 5, 2026
INKT — Latest News & Headlines
5 StoriesA cell therapy enabled killing of immunotherapy-resistant colon cancer cells in a lab model - Stock Titan
A cell therapy enabled killing of immunotherapy-resistant colon cancer cells in a lab model Stock Titan
MiNK Therapeutics’ agenT-797 Selected for ARPA-H BoSS Program to Advance Room-Temperature Cell Therapy Storage - Quiver Quantitative
MiNK Therapeutics’ agenT-797 Selected for ARPA-H BoSS Program to Advance Room-Temperature Cell Therapy Storage Quiver Quantitative
(INKT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
(INKT) Price Dynamics and Execution-Aware Positioning Stock Traders Daily
MiNK’s iNKT platform selected for $87M ARPA-H program By Investing.com - Investing.com Nigeria
MiNK’s iNKT platform selected for $87M ARPA-H program By Investing.com Investing.com Nigeria
Mink Therapeutics, Inc. Announces Selection of Clinical-Stage Agent-797 Inkt Platform for Arpa-H-Funded Initiative to Advance Room-Temperature Cell Therapy - marketscreener.com
Mink Therapeutics, Inc. Announces Selection of Clinical-Stage Agent-797 Inkt Platform for Arpa-H-Funded Initiative to Advance Room-Temperature Cell Therapy marketscreener.com